Valeritas Announces Oral Presentation of Preclinical h-Patch™ CBD Study at the 2nd Annual International Cannabinoid-Derived Pharmaceuticals Summit

BRIDGEWATER, N.J., Sept. 03, 2019 (GLOBE NEWSWIRE) — Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, which uses its proprietary h-Patch™ technology, announced today an oral presentation to be given at the 2nd Annual International Cannabinoid-Derived Pharmaceuticals Summit held in Boston, MA, on September 10-12, 2019. The Summit is dedicated to scientific advances and commercial considerations in the therapeutic use of cannabinoid-derived therapeutics and is a primary industry platform for sharing data critical for the advancement of safe and effective cannabinoid-derived products worldwide. 

Thursday, September 12, 2019
11:15 AM – 11:30 AM ET

  • Leveraging the Valeritas h-Patch™ Drug Delivery Technology to Provide Simple and Effective Continuous Subcutaneous Infusion

On July 30th, https://www.globenewswire.com/news-release/2019/09/03/1909859/0/en/Valeritas-Announces-Oral-Presentation-of-Preclinical-h-Patch-CBD-Study-at-the-2nd-Annual-International-Cannabinoid-Derived-Pharmaceuticals-Summit.html

by